ESSA Pharma (EPI) Stock Price, News & Analysis

Company Overview

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: C$7.33 to C$8.20
• 50-Day Range: C$8.20 to C$8.20
• 52-Week Range: C$4.00 to C$11.34
• Volume: 1,430 shs
• Average Volume: 4,834 shs
• Market Capitalization: C$237.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EPI Stock Analysis - Frequently Asked Questions

How have EPI shares performed this year?

ESSA Pharma's stock was trading at C$8.20 on January 1st, 2025. Since then, EPI stock has increased by 0.0% and is now trading at C$8.20.

How do I buy shares of ESSA Pharma?

Shares of EPI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of ESSA Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ESSA Pharma investors own include Aurora Cannabis (ACB), Air Canada (AC), Arbutus Biopharma (ABUS), AB Science (ABSCF), AB International Group (ABQQ), AB Dynamics (ABDP) and Advantage Energy (AAV).

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: CVE:EPI
• CIK: N/A
• Web: essapharmaceuticals.com
• Phone: +1-778-3310962
• Fax: N/A
• Employees: 25
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 37.29
• Quick Ratio: 36.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$2.21 per share
• Price / Cash Flow: 3.72
• Book Value: C$2.21 per share
• Price / Book: 3.72

Miscellaneous

• Outstanding Shares: 29,009,000
• Free Float: N/A
• Market Cap: C$237.87 million
• Optionable: Not Optionable
• Beta: N/A